ViewRay (VRAYQ) Aandeel Koers
ViewRay Koers
De omzet is de afgelopen 10 jaar met 49,3% per jaar gegroeid tot 102,21 Miljoen USD. De nettowinstmarge van ViewRay ligt op -105,0% en is ten opzichte van -94,4% enkele jaren eerder gedaald.
ViewRay aandeelkoers
ViewRay bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over ViewRay
ViewRay Inc is a medical technology company specializing in advanced radiation therapy solutions. Their business model revolves around developing and manufacturing MRIdian, a revolutionary MRI-guided radiotherapy system. By seamlessly integrating high-quality magnetic resonance imaging with precise radiation delivery, ViewRay aims to improve cancer treatment outcomes. This innovative technology allows real-time visualization of tumors and surrounding healthy tissues, enabling physicians to optimize treatment plans. ViewRay Inc focuses on providing cutting-edge solutions for the cancer care industry, ultimately aiming to enhance patient care and revolutionize the way radiation therapy is administered.
ViewRay Inc is primarily active in the healthcare industry.
The main competitors of ViewRay Inc in the market include Varian Medical Systems, Elekta AB, Accuray Incorporated, and Siemens Healthineers.
ViewRay Inc is a leading medical technology company focused on designing, manufacturing, and selling innovative radiation therapy systems. Founded in 2004, ViewRay has emerged as a pioneer in the field of MRI-guided radiation therapy, revolutionizing cancer treatment and improving patient outcomes. The company's flagship product, the MRIdian® system, integrates MRI technology with radiation therapy to provide real-time imaging and accurate target localization during treatment. ViewRay's cutting-edge solutions have garnered recognition worldwide and have been adopted by renowned cancer centers. With a strong commitment to innovation and patient care, ViewRay Inc continues to shape the future of radiation therapy.
ViewRay Inc has achieved several significant milestones throughout its history. Notably, the company received FDA clearance for its MRIdian Linac system, a state-of-the-art cancer treatment technology that combines MRI imaging with radiation therapy. This groundbreaking technology allows for real-time visualization of tumors during treatment, enabling precise and accurate delivery of radiation to targeted areas. The company has also successfully expanded its global presence, with installations of the MRIdian system in various prestigious cancer centers worldwide. Furthermore, ViewRay Inc has continually demonstrated its commitment to innovation and research, driving advancements in the field of radiation therapy for improved patient outcomes.
ViewRay Inc is primarily present in the United States.
ViewRay Inc represents values of innovation, precision, and patient-centricity. With a corporate philosophy focused on improving cancer treatment, ViewRay Inc develops advanced radiation therapy technology called MRIdian. Using real-time MRI guidance, this cutting-edge system enables physicians to deliver precise, personalized radiation therapy for cancer patients. Through continuous innovation and a commitment to improve the standard of care, ViewRay Inc aims to empower healthcare providers in their mission to effectively treat cancer. By integrating advanced imaging and treatment capabilities, the company strives to enhance patient outcomes and quality of life.
14 analisten beoordelen het aandeel ViewRay momenteel: 8 adviseren kopen, 6 houden en 0 verkopen.
Omgezet tegen de huidige wisselkoers noteert het aandeel ViewRay op 0,00 EUR (0,00 USD).
Het aandeel ViewRay (VRAYQ) is genoteerd aan 3 beurzen, waaronder: NASDAQ (VRAY), Frankfurt (6L9.F), München (6L9.MU).
ViewRay Inc. is an emerging American company that develops and sells innovative products and solutions in the field of medical technology. Their main business is the manufacturing and marketing of advanced radiation therapy systems that enable doctors to treat cancer patients with higher precision and efficacy. ViewRay Inc.'s business model includes the development and marketing of MRIdian®, a unique radiation therapy system based on magnetic resonance imaging (MRI). MRIdian® allows doctors to precisely control and monitor the radiation dose, ensuring precise and gentle treatment. This system is an ideal solution for patients with cancer in sensitive areas such as the brain, breast, or prostate. Another important aspect of ViewRay Inc.'s business model is conducting clinical studies to demonstrate the efficacy and safety of MRIdian® and other products in the pipeline. These studies are crucial for obtaining regulatory approval and market access. ViewRay Inc. is also engaged in research and development to create new technologies and products that allow doctors to more effectively combat cancer. For example, they are integrating artificial intelligence (AI) into MRIdian® systems to improve cancer diagnosis and treatment precision and speed. In addition to selling radiation therapy systems, ViewRay Inc. provides comprehensive service and support to ensure that the systems are always in optimal condition and patients are well cared for. They offer training for doctors and technical personnel to ensure they have the necessary knowledge and skills to safely and effectively use the MRIdian® system. ViewRay Inc. has also established partnerships and collaborations with other companies and organizations worldwide to expand its reach and offerings. For instance, they have a partnership with Elekta, a leading provider of medical imaging systems, to distribute their technology in Europe and Asia. In summary, ViewRay Inc. is an innovative company focused on developing and marketing high-quality radiation therapy systems to provide precise, gentle, and effective treatment for cancer patients. They are also actively involved in research and development to create new technologies and products for more effective cancer treatment. With a comprehensive range of service and support, as well as partnerships and collaborations, ViewRay Inc. is well positioned to continue growing and make a significant contribution to cancer fighting.
De omzet kan momenteel niet worden berekend voor ViewRay.
De winst kan momenteel niet worden berekend voor ViewRay.
De P/E-ratio kan momenteel niet worden berekend voor ViewRay.
De P/S-ratio kan momenteel niet worden berekend voor ViewRay.
De Eulerpool Kwaliteitsscore voor ViewRay is 4/10.
De ISIN van ViewRay is US92672L1070. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van ViewRay is A2AE2S. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van ViewRay is VRAYQ. Onder dit beurstickersymbool wordt het ViewRay-aandeel op de beurs verhandeld.
ViewRay aandeel
ViewRay Peer Group
ViewRay Ticker
ViewRay FIGI
Alle fundamentals en diepgaande analyse van ViewRay
Onze aandelenanalyse van het ViewRay-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van ViewRay. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: